Aurora Kinases in Ovarian Cancer

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2020 Oct 22

PMID 33087400

Citations 9

Authors

J Alejandro Perez-Fidalgo

Valentina Gambardella

Begona Pineda

Octavio Burgues

Oscar Pinero

Andres Cervantes

Affiliations

Soon will be listed here.

Abstract

Aurora kinases (AURK) are key regulators of the mitotic spindle formation. AURK is frequently overexpressed in ovarian cancer and this overexpression has been frequently associated with prognosis in these tumours. Interestingly, AURK have been shown to interact with DNA repair mechanisms and other cell cycle regulators. These functions have brought light to Aurora family as a potential target for anticancer therapy. In the last years, two clinical trials with different AURK inhibitors have shown activity in epithelial and clear-cell ovarian cancer. Although there is a lack of predictive factors of AURK inhibition activity, recent trials have identified some candidates. This review will focus in the functions of the AURK family, its role as prognostic factor in epithelial ovarian cancer and potential clinical implications.

Citing Articles

De-regulation of aurora kinases by oncogenic HPV; implications in cancer development and treatment.

Oladipo K, Parish J Tumour Virus Res. 2025; 19:200314.

PMID: 39923999 PMC: 11867274. DOI: 10.1016/j.tvr.2025.200314.

Exploiting Cancer Dormancy Signaling Mechanisms in Epithelial Ovarian Cancer Through Spheroid and Organoid Analysis.

Tomas E, Valdes Y, Davis J, Kolendowski B, Buensuceso A, DiMattia G Cells. 2025; 14(2).

PMID: 39851561 PMC: 11764263. DOI: 10.3390/cells14020133.

Aurora kinase A expression in pleomorphic adenoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma of salivary glands: an immunohistochemical study.

Zare R, Izadi L, Alarcon-Sanchez M, Taghva M, Ranjbar M BMC Oral Health. 2025; 25(1):89.

PMID: 39825351 PMC: 11740330. DOI: 10.1186/s12903-024-05276-5.

Novel bis-benzimidazole-triazole hybrids: anticancer study, in silico approaches, and mechanistic investigation.

Soliman M, Ahmed H, Eltamany E, Boraei A, Aljuhani A, Salama S Future Med Chem. 2024; 17(1):93-107.

PMID: 39670306 PMC: 11702989. DOI: 10.1080/17568919.2024.2437980.

Aurora kinase as a putative target to tick control.

Moraes B, Gomes H, Saramago L, Braz V, Parizi L, Braz G Parasitology. 2024; 151(9):983-991.

PMID: 39542861 PMC: 11770520. DOI: 10.1017/S003118202400101X.

References

Carmena M, Earnshaw W . The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003; 4(11):842-54. DOI: 10.1038/nrm1245. View

Alcaraz-Sanabria A, Nieto-Jimenez C, Corrales-Sanchez V, Serrano-Oviedo L, Andres-Pretel F, Carlos Montero J . Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer. Mol Cancer Ther. 2017; 16(11):2552-2562. DOI: 10.1158/1535-7163.MCT-17-0223. View

Gonzalez-Loyola A, Fernandez-Miranda G, Trakala M, Partida D, Samejima K, Ogawa H . Aurora B Overexpression Causes Aneuploidy and p21Cip1 Repression during Tumor Development. Mol Cell Biol. 2015; 35(20):3566-78. PMC: 4573715. DOI: 10.1128/MCB.01286-14. View

Lee Y, Choi E, Kim M, Park P, Park N, Lee H . BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers. Br J Cancer. 2009; 101(3):504-10. PMC: 2720250. DOI: 10.1038/sj.bjc.6605161. View

Yan M, Wang C, He B, Yang M, Tong M, Long Z . Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy. Med Res Rev. 2016; 36(6):1036-1079. DOI: 10.1002/med.21399. View

Do T, Xiao F, Bickel L, Klein-Szanto A, Pathak H, Hua X . Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene. 2013; 33(5):539-49. PMC: 3640671. DOI: 10.1038/onc.2012.632. View

Ma Y, Cao H, Lou S, Shao X, Lv W, Qi X . Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc. J Mol Med (Berl). 2014; 93(4):427-38. DOI: 10.1007/s00109-014-1228-0. View

He Y, Jiang W, Qian X, Liu F, Zhang Q, You C . Role of Aurora-A in Ovarian Cancer: A Meta-Analysis. Oncol Res Treat. 2015; 38(9):442-7. DOI: 10.1159/000439194. View

Mendiola M, Barriuso J, Marino-Enriquez A, Redondo A, Dominguez-Caceres A, Hernandez-Cortes G . Aurora kinases as prognostic biomarkers in ovarian carcinoma. Hum Pathol. 2009; 40(5):631-8. DOI: 10.1016/j.humpath.2008.10.011. View

10.

Hsueh K, Fu S, Chang C, Chang Y, Lin C . A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2. Biochim Biophys Acta. 2012; 1834(2):508-15. DOI: 10.1016/j.bbapap.2012.11.005. View

11.

Traynor A, Hewitt M, Liu G, Flaherty K, Clark J, Freedman S . Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010; 67(2):305-14. PMC: 3050703. DOI: 10.1007/s00280-010-1318-9. View

12.

Sun C, Chan F, Briassouli P, Linardopoulos S . Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents. Biochem Biophys Res Commun. 2006; 352(1):220-5. DOI: 10.1016/j.bbrc.2006.11.004. View

13.

Hou M, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D . Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016; 7(23):35132-43. PMC: 5085215. DOI: 10.18632/oncotarget.9048. View

14.

Das K, Lorena P, Ng L, Shen L, Lim D, Siow W . Aurora-A expression, hormone receptor status and clinical outcome in hormone related cancers. Pathology. 2010; 42(6):540-6. DOI: 10.3109/00313025.2010.508789. View

15.

Kulkarni A, Loddo M, Leo E, Rashid M, Eward K, Fanshawe T . DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma. Clin Cancer Res. 2007; 13(20):6153-61. DOI: 10.1158/1078-0432.CCR-07-0671. View

16.

Zhou J, Li L, Wang L, Li X, Xing H, Cheng L . Establishment of a SVM classifier to predict recurrence of ovarian cancer. Mol Med Rep. 2018; 18(4):3589-3598. PMC: 6131358. DOI: 10.3892/mmr.2018.9362. View

17.

Hetland T, Nymoen D, Holth A, Brusegard K, Florenes V, Kaern J . Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance. Hum Pathol. 2012; 44(5):777-85. DOI: 10.1016/j.humpath.2012.08.002. View

18.

Yang G, Chang B, Yang F, Guo X, Cai K, Xiao X . Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res. 2010; 16(12):3171-81. PMC: 2930838. DOI: 10.1158/1078-0432.CCR-09-3171. View

19.

Bolton M, Lan W, Powers S, McCleland M, Kuang J, Stukenberg P . Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell. 2002; 13(9):3064-77. PMC: 124143. DOI: 10.1091/mbc.e02-02-0092. View

20.

Zhan S, Liu B, Linghu H . Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis. Oncol Rep. 2018; 39(6):2653-2663. PMC: 5983937. DOI: 10.3892/or.2018.6383. View